Mucosal-associated invariant T (MAIT) cells express a semi-invariant Vα7.2 + T cell receptor (TCR) that recognizes ligands from distinct bacterial and fungal species. In neonates, MAIT cells proliferate coincident with gastrointestinal (GI) bacterial colonization. In contrast, under noninflammatory conditions adult MAIT cells remain quiescent because of acquired regulation of TCR signaling. Effects of inflammation and the altered GI microbiota after allogeneic hematopoietic cell transplantation (HCT) on MAIT cell reconstitution have not been described. We conducted an observational study of MAIT cell reconstitution in myeloablative (n = 41) and nonmyeloablative (n = 66) allogeneic HCT recipients and found that despite a rapid and early increase to a plateau at day 30 after HCT, MAIT cell numbers failed to normalize for at least 1 year. Cord blood transplant recipients and those who received post-HCT cyclophosphamide for graft versus host disease (GVHD) prophylaxis had profoundly impaired MAIT cell reconstitution. Sharing of TCRβ gene sequences between MAIT cells isolated from HCT grafts and blood of recipients after HCT showed early MAIT cell reconstitution was due at least in part to proliferation of MAIT cells transferred in the HCT graft. Inflammatory cytokines were required for TCR-dependent MAIT cell proliferation, suggesting that bacterial Vα7.2 + TCR ligands might promote MAIT cell reconstitution after HCT. Robust MAIT cell reconstitution was associated with an increased GI abundance of Blautia spp. MAIT cells suppressed proliferation of conventional T cells consistent with a possible regulatory role. Our data identify modifiable factors impacting MAIT cell reconstitution that could influence the risk of GVHD after HCT.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is complicated by perturbed immune reconstitution, resulting in an increased risk of infections and inflammatory complications, such as graftversushost disease (GVHD) [1] . Although the composition in the HCT graft of conventional αβT cell subsets has been shown to influence the incidence of immune-mediated complications of transplant [2] [3] [4] , the roles of nonconventional T cell subsets in immune reconstitution after HCT are poorly defined.
Mucosal-associated invariant T (MAIT) cells comprise a subset of non-conventional T cells that are characterized by high expression of CD161 and RORγ and a TCR comprising an invariant Vα7.2 + TCRα chain paired with 1 of a diverse repertoire of TCRβ chains. MAIT cells recognize metabolite antigens derived from distinct gastrointestinal (GI) bacterial and fungal species that are presented by the MHC class 1-like molecule, MR1 [5] [6] [7] [8] [9] . Despite GI colonization with bacterial species capable of activating MAIT cells, MAIT cells in adults are remarkably quiescent because of acquired regulation of the TCR signaling pathway [10] . However, in vitro studies show the regulation of proliferation and effector function of MAIT cells can be overcome by TCR stimulation in the presence of proinflammatory cytokines, including IL-12 and IL-18 [10, 11] . These data suggest that inflammatory signals induced by conditioning chemotherapy, radiation, allogeneic cell infusion, and altered GI mucosal integrity, along with lymphopenia and antibiotic-induced changes in the composition of the GI microbiota, might affect MAIT cell reconstitution and function after allogeneic HCT [12, 13] .
In this prospective observational study of recipients of allogeneic peripheral blood stem cell (PBSC) grafts, we observed that reconstitution of donor MAIT cells in blood was incomplete and occurred with kinetics that were distinct from those of conventional lymphocytes and neutrophils. Early MAIT cell reconstitution was driven by proliferation of MAIT cells that were directly transferred in the HCT graft, suggesting that restraint of effector function in MAIT cells was overcome in vivo by the post-HCT inflammatory milieu. Studies of TCRβ chain gene (TRBV) sequence utilization in MAIT cells isolated at different times after HCT demonstrated expansion and contraction of distinct MAIT cell clones, suggesting that MAIT cell reconstitution may in part be governed by antigen stimulation. We established that robust MAIT cell reconstitution in blood correlated with abundance of distinct bacterial species in stool of HCT recipients and a lower risk of subsequent development of grade ≥ III acute GVHD.
METHODS

Blood and HCT Graft Samples
Blood from healthy donors and HCT recipients and granulocyte colonystimulating factor-mobilized leukapheresis products from HCT donors were obtained after written informed consent. Blood and stool samples were collected from HCT recipients before conditioning and at approximately days 0, 10, 20, 30, 60, 100, and 365 after HCT. Studies were performed according to the guidelines of the Declaration of Helsinki and were approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center.
Antibodies and Cytokines
Fluorochrome-conjugated monoclonal antibodies (mAbs are described in Supplementary Table S1 . Recombinant human IL-1β, IL-12, and IL-23 were obtained from R&D Systems (Minneapolis, MN) and IL-18 from MBL International (Woburn, MA). IL-1β, IL-12, IL-18, and IL-23 were used in culture at 10 ng/mL.
Immunophenotyping
Peripheral blood mononuclear cells (PBMCs) were stained with live/ dead fixable violet stain (Thermofisher Scientific, Waltham, MA) and mAbs specific for surface antigens, followed by acquisition on an LSR-II flow cytometer (BD Biosciences, San Jose, CA) and analysis using FlowJo software version 9.8 (FlowJo, Ashland, OR). MAIT cells were identified as viable CD45 + / CD3 + /CD161 hi /Vα7.2 + events. Absolute MAIT cell counts in blood were determined by multiplying the percentage of MAIT cells in a CD45 + lymphoid forward-scatter and side-scatter gate by the absolute lymphocyte count performed on the same day. The absolute MAIT cell count in PBSC graft samples is reported as MAIT cells/kg recipient weight and was determined by multiplying the MAIT cell percentage in a viable CD45 + /CD3 + gate by the absolute graft CD3 count.
MAIT Cell Isolation
Healthy donor CD8 + cells were enriched from Ficoll-separated peripheral blood mononuclear cells using the CD8 + T cell isolation kit (Miltenyi, Auburn, CA). MAIT cells (identified as CD3 + /CD8 + /CD161 hi /Vα7.2 + events) and conventional T cells (CD3 + /CD8 + /CD161 lo /Vα7.2 − events) were sort purified from enriched CD8 + T cells using a FACS ARIA 2 flow sorter (BD Biosciences).
Activation and Proliferation Assays
Isolated MAIT and conventional T cell subsets were activated or not with plate-bound αCD3 (OKT3; Ortho Biotech, Bridge Water, NJ) and cultured in 96-well plates at 1 to 2 × 10 4 cells/well in 200 μL RPMI 1640 medium with 10% human serum, penicillin/streptomycin, β-mercaptoethanol, and L-glutamine with or without cytokine supplementation. To assess the immunophenotype in response to stimulation, isolated cells were cultured overnight before analysis by flow cytometry. Proliferation of isolated MAIT and conventional T cells after 4 days of stimulation in culture was evaluated by addition of tritiated thymidine (30 μCi/well) for the last 18 hours, followed by assessment of tritiated thymidine incorporation. The stimulation index was determined as the ratio of counts obtained in the presence of stimulation divided by counts obtained in the absence of stimulation.
Flow Cytometry of TCR Signaling Pathway Phosphoproteins
Whole blood was incubated with anti-CD62L and anti-CD161 for 10 minutes, followed by RBC lysis and αCD3 (OKT3) stimulation at 37°C for 10 minutes. Cells were immediately fixed and incubated with anti-CD45RA and then permeabilized and stained with anti-CD3, -CD4, and -Vα7.2 and either Lck (pY505), CD3ζ (pY142), or ZAP70 (pY292) for 60 minutes at room temperature using an optimized Phosflow protocol (BD Biosciences) for TCR stimulation.
Donor-Recipient Chimerism Studies
Short tandem repeat PCR chimerism studies were used to determine comparative donor and HCT recipient chimerism status in sort purified MAIT, CD33 + myeloid, conventional CD3 + T cell, and CD56 + natural killer cell subsets from recipient blood samples using a modified Powerplex 16 System (Promega, Madison, WI). Short tandem repeat fragments were PCR amplified from extracted DNA using the PowerPlex 16 Human Identity Kit (Promega) followed by separation of variable length amplified fragments by capillary gel electrophoresis using the ABI 3130x1-16 array capillary system (ThermoFisher Scientific) and analysis using GeneMapper ID software (Applied Biosystems, Foster City, CA).
TRBV Sequencing
MAIT cells were sorted from PBSC grafts and from the peripheral blood of healthy donors and HCT recipients, and DNA was extracted for highthroughput CDR3β region gene sequencing (Adaptive Biotechnologies, Seattle, WA) [14] . The CDR3β sequences from samples were amplified in a multiplex PCR system using forward and reverse primers for the Vβ and Jβ segments, respectively, generating 60-bp amplicons that were sequenced using the Illumina HiSeq platform (San Diego, CA). Primer amplification bias was corrected using a suite of synthetic templates, and the International Immunogenetics Database (www.imgt.org) was used to filter the raw sequence data for subsequent analysis by the ImmunoSEQ analyzer toolset (www.adaptivebiotech.com/immunoseq). TRBV sequence diversity was calculated as the productive entropy (summing the productive frequency times the log [base 2] of the same frequency over all productive rearrangements in a sample).
Microbiota Profiling
Broad-range 16S rRNA gene PCR with pyrosequencing and phylogenetic assignment was used to profile the stool bacterial biota in HCT recipients. DNA was extracted from fecal swabs using the BiOstic Bacteremia DNA Isolation kit (MoBio, Carlsbad, CA) and eluted in 150 μL elution buffer (75 μL MoBio elution buffer, 75 μL .2× filtered 1 mM Tris, .1 mM EDTA buffer). Broadrange 16S rRNA gene quantitative PCR was used to measure total bacterial load [15] , and PCR inhibition was monitored using an internal amplification control [16] . Conventional broad-range 16S rRNA gene PCR targeting the V3-V4 region of the 16S rRNA gene was coupled with pyrosequencing of the amplified fragments using the 454 Life Sciences Titanium technology (Roche, Branford, CT) [15, 17] . No-template PCR and sham DNA extraction controls without human contact were run with each PCR assay to monitor for contamination. Samples were multiplexed with 6-bp barcodes. Sequence reads were classified using a curated reference set of GI bacteria and the pplacer phylogenetic placement tool [18] . Sample identifiers and barcodes used for GI microbial species sequencing are shown in Supplementary  Table S2 . Blood and stool samples used for correlation of MAIT cell counts and bacterial abundance, respectively were collected within a week of each other.
In Vitro Suppressive Assay
MAIT cells, identified as Vα7.2 + CD161 + cells, and CD4 + CD25 − responder T cells were sorted from the peripheral blood of 3 healthy donors. Responder T cells were labeled with .5 μM CFSE (Carboxyfluorescein succinimidyl ester); 2.5 × 10 4 CFSE-labeled responder T cells were stimulated with Dynabeads CD3/CD28 T Cell Expander (Dynal Biotech, Invitrogen, Carlsbad, CA) and cultured with MAIT cells or responder T cells at a ratio of 1:1, 1:2, 1:4, and 1:8 MAIT-to-responder in round-bottom 96-well plates for 4 days. After 4 days CFSE dilution was evaluated by flow cytometry.
Statistical Methods
Cox regression methods were used to assess the association between MAIT cell count and the cause-specific hazards of failure for the outcome of acute GVHD. The MAIT cell count was modeled as a linear, time-dependent covariate using SAS version 9.4 (SAS Institute, Cary, NC). An unpaired 2-tailed Mann-Whitney test was used to evaluate differences in MAIT cell counts after HCT. A paired 2-tailed Student's t-test was used to compare phosphorylated protein expression between MAIT and conventional T cells and activation markers in stimulated and nonstimulated MAIT cells. Data are represented as mean ± standard error of mean, except where indicated in the figure legends. P < .05 is considered to represent a significant difference. Graphs and accompanying statistical analyses were generated using Prism version 6.02 (GraphPad, La Jolla, CA).
RESULTS
Kinetics of MAIT Cell Recovery in Blood after HCT
We conducted a prospective, observational study to evaluate the kinetics of MAIT cell recovery in HLA-matched or single HLA antigen-mismatched peripheral blood stem cell transplant (PBSCT) recipients after myeloablative (MA, n = 41) or nonmyeloablative (NMA, n = 66) conditioning. Patient and transplant characteristics are summarized in Supplementary  Table S3 . Absolute peripheral blood MAIT cell counts were measured before initiation of the conditioning regimen in pre-HCT patients and compared with MAIT cell counts in normal donors. There was variation in MAIT cell counts in healthy individuals, and this variation was more extreme in patients who also had significantly lower MAIT cell numbers than healthy donors ( Figure 1A ).
MA and NMA regimens differ in the severity of lymphopenia and mucosal injury, which are factors that could influence MAIT cell reconstitution, either from residual host or transplanted donor cells. After both MA and NMA conditioning therapy, absolute MAIT cell counts in blood decreased to a nadir on the day of PBSC infusion ( Figure 1B ,C). The MAIT cell nadir occurred earlier than the absolute neutrophil count nadir and was followed by early and rapid recovery to a plateau from day 30 to day 100 after HCT. MAIT cell counts remained lower than those of healthy donors for at least 1 year after HCT ( Figure 1D ).
We identified no differences in MAIT cell reconstitution at early or late times in patients receiving MA or NMA conditioning ( Figure 1E ), and at all time points after HCT we observed a similar marked variation in the magnitude of MAIT cell counts in blood between different individuals as observed before HCT ( Figure 1F ). Incorporation of total body irradiation in conditioning, use of an HLA matched related compared with unrelated PBSC donor, use of an HLA matched compared with mismatched PBSC donor, and the indication for transplant (acute leukemia versus other diagnoses) did not impact MAIT cell recovery (Supplementary Figure S1 ).
MAIT Cells Transferred in the HCT Graft Contribute to MAIT Cell Reconstitution
We considered that the variability in MAIT cell reconstitution between patients after HCT could in part be due to differences in the numbers of MAIT cells transferred in the HCT graft and that their in vivo activation and proliferation may account for the rapid and early increase in MAIT cell counts after HCT. We found that the frequency of MAIT cells that expressed CD69 was higher in PBSCT recipients at day 10 post-HCT compared with that in healthy donors (4.6%, n = 5) or in PBSC grafts (6.0%, n = 6; Figure 2A ), consistent with early MAIT cell activation in the post-HCT inflammatory milieu. This early activation of MAIT cells coincided with a greater fraction in the cell cycle as measured by the frequency of cells expressing the proliferation marker Ki67. Although MAIT cells in HCT grafts expressed Ki67 at levels similar to those from healthy individuals (Ki67 + , healthy donors, .38%, n = 5; PBSC grafts, 1.30%, n = 6; P = .42), the fraction of Ki67 + MAIT cells had increased more than 10-fold in the recipient compared with the PBSC graft by day 10 after HCT ( Figure 2B ). We identified no difference in the fraction of Ki67 + MAIT cells after MA or NMA HCT ( Figure 2C ).
Because MAIT cells efflux ABCB1 substrate drugs [19] , it was unknown if recipient MAIT cells could survive conditioning chemotherapy and contribute to early MAIT cell recovery or if early MAIT cell recovery was donor-derived. To address this question we performed short tandem repeat PCR chimerism studies on CD3 + T cells, CD33 + myeloid cells, CD56 + cells, and sort-purified MAIT cells isolated from the blood of HCT recipients. We found that at 30 and 100 days after both NMA and MA HCT, MAIT cells were nearly exclusively of donor origin ( Figure 2D ). MAIT cell numbers in blood of HCT recipients on day 30 and day 100 after HCT correlated with the number of MAIT cells transferred in the PBSC graft ( Figure 2E) . In contrast, we did not observe an association between MAIT cell reconstitution and the number of CD34 + cells in the PBSC graft ( Figure 2F ) or with the number of graft CD19 + B cells, which are required for neonatal MAIT cell accumulation (Supplementary Figure S2) [8] .
To determine whether MAIT cells that are transferred in the PBSC graft contribute to MAIT cell recovery in the recipient, we sequenced the TRBV genes in MAIT cells isolated from an aliquot of the PBSC graft and from the recipient's blood (n = 5) and evaluated the fraction of sequences in the recipient that were also found in the PBSC graft. Compared with the low level of sharing between pairs of unrelated individuals (.4% ± .15%, n = 42), a large fraction of TRBV sequences was shared between donor PBSC grafts and the blood of each graft recipient at day 30 (17.1%, P < .001), day 100 (15.6%, P < .001), and 1 year (5.4%, P = .01) after PBSCT ( Figure 2G,H) . Together, the data indicate that direct transfer of MAIT cells and possibly MAIT cell precursors in the donor PBSC graft contributes to MAIT cell recovery in the recipient.
MAIT Cell Reconstitution Is Impaired after Umbilical Cord Blood Transplant and Haploidentical PBSCT with Post-HCT Cyclophosphamide
We investigated the kinetics of MAIT cell recovery in recipients of umbilical cord blood (UCB) grafts, which contain markedly lower numbers of mature MAIT cells than adult PBSC grafts [10] . We examined MAIT cell counts in blood of recipients of double UCB (DUCB) HCT (MA, n = 3; NMA, n = 3) and found that recipients of DUCB grafts had profoundly impaired recovery of MAIT cells compared with PBSCT recipients at all times up to and including 1 year after HCT ( Figure 3A,B ). Because MAIT cell reconstitution is dependent on proliferation of MAIT cells that are transferred in the HCT graft, we also investigated the impact of administration of post-HCT cyclophosphamide for GVHD prophylaxis to recipients of haploidentical PBSCT (n = 6) and found that like DUCB HCT recipients, patients who received PBSCT with post-HCT cyclophosphamide had poor MAIT cell recovery compared with recipients of PBSC grafts without post-HCT cyclophosphamide ( Figure 3A) .
MAIT Cells Are Activated by Inflammatory Cytokines, but TCR Stimulation Is Required for Robust Proliferation
After HCT, patients have a compromised GI mucosal barrier, altered microbiota, and release of inflammatory cytokines, which could activate MAIT cells [13, 20, 21] . To determine whether inflammatory cytokines are sufficient to promote recipient MAIT cell reconstitution by inducing proliferation of MAIT cells transferred in the HCT graft or if TCR signaling is also required, we established in vitro assays to study the effect of inflammatory cytokines alone or with TCR stimulation on activation and proliferation of adult healthy donor MAIT cells. MAIT cells stimulated with anti-CD3 (OKT3) mAb alone failed to upregulate Ki67 and proliferate and exhibited reduced Lck, ZAP-70 and CD3ζ phosphorylation compared with naive, central, and effector memory subsets of conventional CD8 + T cells ( Figure 4A, Supplementary Figure S3 ), consistent with our previous work that identified downregulation of genes encoding components of the proximal TCR signaling pathway in MAIT cells [10] . Co-culture of MAIT cells with individual inflammatory cytokines at concentrations similar to those found in serum of HCT recipients [22, 23] was sufficient to induce CD69 expression in a small fraction of MAIT cells ( Figure 4B ) but was insufficient to completely overcome regulation of proximal TCR pathway signaling and induce MAIT cell Ki67 expression and proliferation ( Figure 4C , Supplementary Figure S3 ), which was only induced by the combination of inflammatory cytokine stimulation in conjunction with TCR stimulation ( Figure 4C ). These data suggest that inflammatory cytokines released in the post-HCT milieu may prime MAIT cells, with robust activation and proliferation only occurring after additional stimulation through the semi-invariant MAIT cell TCR.
MAIT Cell Reconstitution Correlates with the Abundance of Distinct Bacterial Species in the GI Tract
Our findings suggested that in addition to inflammatory cytokines in the post-HCT milieu, stimulation of the semiinvariant Vα7.2 + TCR might be required to induce proliferation in MAIT cells after transfer in the HCT graft. We examined the TRBV repertoire in MAIT cells that were isolated from the blood of HCT recipients and found that TRBV diversity was similar in healthy donors and PBSCT recipients; however, in contrast to the stability of the TCR repertoire in MAIT cells from healthy donors [24] , there was variability in TRBV diversity ( Figure 5A ), sequence sharing ( Figure 5B) , and the contribution of distinct TRBV clonotypes ( Figure 5C ) in the MAIT cell repertoire at different times after HCT, indicative of alteration in the clonal composition of MAIT cells over time in HCT recipients. Alteration in the TRBV sequence composition of MAIT cells after stimulation with distinct bacterial species suggests that MAIT cells have the capacity to discriminate between TCR ligands derived from different bacterial species [25] . Therefore, we considered that distinct bacterial species in the GI microbiota might contribute to TCRmediated proliferation and reconstitution of MAIT cells after allogeneic HCT, as occurs after GI microbial colonization in neonates. We characterized the composition of the GI microbiota by performing 16S rRNA gene PCR on stool samples collected at distinct times after HCT followed by highthroughput sequencing of the amplified fragments and phylogenetic assignment and, in parallel, collected blood samples for evaluation of MAIT cell recovery to determine if the abundance of distinct bacterial species correlated with MAIT cell numbers in blood. The GI microbiota after HCT was dynamic, consistent with the known effects of mucosal injury due to conditioning therapy, antibiotic use, and altered dietary intake on the microbiota ( Figure 5D ). Higher abundance of Blautia spp. and Bifidobacterium longum were each associated with higher MAIT cell counts in blood ( Figure 5E ).
Impaired MAIT Cell Reconstitution May Be Associated with an Increased Risk of Acute GVHD
Higher abundance of Blautia spp. in the stool of HCT recipients was associated with a reduced risk of acute GVHD requiring systemic immunosuppression and reduced GVHDrelated mortality [26] . We therefore investigated whether MAIT cell reconstitution might also impact the risk of acute GVHD and found that HCT recipients who developed severe (grades III to IV) acute GVHD had lower MAIT cell counts in blood compared with those without acute GVHD ( Figure 6A ). To confirm that the observed association between low MAIT cell counts and GVHD was not because of the effects of treatment for GVHD, we performed multivariate Cox regression modeling with MAIT cell counts as a time-dependent covariate, excluding MAIT cell counts after the diagnosis of GVHD. After adjusting for the recipient age, absolute neutrophil count, donor type (unrelated versus related), and conditioning regimen (MA versus NMA), we found that an increase in MAIT cell count in blood in the early post-HCT period was associated with reduced risk of subsequent development of GVHD (hazard ratio was .76 for acute GVHD for every 10 cells/μL increase in MAIT counts [95% confidence interval, .51 to 1.14, P = .18]). In vitro studies demonstrated that activated MAIT cells suppressed proliferation of CD4 + T cells in a co-culture assay ( Figure 6B , Supplementary Figure S4 ). These data suggest that factors that impair MAIT cell recovery after HCT could increase the risk of acute GVHD.
DISCUSSION
We present longitudinal data from 107 PBSCT recipients showing that early MAIT cell reconstitution in blood after allogeneic HCT is dependent on transfer of MAIT cells in the HCT graft and their subsequent activation and proliferation in the recipient after HCT. Our in vitro data demonstrate that MAIT cell proliferation was only induced by TCR stimulation in the presence of inflammatory cytokines and not by either TCR stimulation or inflammatory cytokines alone. These data suggest that innate cytokines that are elevated in HCT recipients after conditioning therapy and infusion of allogeneic cells may prime MAIT cells but that TCR stimulation may be required for full activation, proliferation, and robust reconstitution. Stimulation of the MAIT cell TCR can be provided by bacterial ligands, including riboflavin metabolites [9] , whose impact on MAIT cell proliferation may be modified after HCT by alteration in absorption and changes in the composition of the GI microbiota because of GI mucosal injury after cytotoxic conditioning therapy, perturbed diet, parenteral feeding, and antibiotic use [27] . We investigated whether distinct bacterial species in the GI tract were associated with MAIT cell reconstitution and found that Blautia spp. and B. longum abundance in stool after HCT correlated with MAIT cell counts in blood. Although distinct Blautia species metabolize riboflavin [28] , additional studies will be required to determine if MAIT cell reconstitution is predominantly governed by riboflavin metabolites produced by Blautia spp. or other species and if other ligands also stimulate the semi-invariant TCR and drive MAIT cell reconstitution.
Our finding that MAIT cell counts rapidly increased in the first 30 days after HCT but failed to reach normal levels up to 1 year after HCT was intriguing. Despite the ongoing presence of bacterial ligands in the GI tract, there was limited MAIT cell proliferation and accumulation beyond 30 days after HCT, which could in part be due to limitation of available innate cytokines after resolution of inflammation after hematopoietic engraftment, with subsequent restoration of TCR signaling pathway regulation. Alternatively, lack of bacterial diversity in the gut after HCT could limit availability of MAIT TCR ligands, suggesting that antimicrobial prophylaxis, therapy, or gut decontamination practices might be important factors in governing MAIT cell reconstitution. MAIT cells may also be more prone to replicative senescence associated with short telomeres and expression of the proapoptotic gene, PLZF [29, 30] . Additional studies will be required to establish whether immunosuppressive agents used to prevent or treat GVHD impact MAIT cell recovery. We observed that MAIT cell reconstitution was markedly impaired in recipients of haploidentical transplantation who received post-HCT cyclophosphamide and in recipients of UCB, which contains few MAIT cells. Although studies in murine models suggest that MAIT cells may contribute to mucosal immunity to bacterial infection, especially in the setting of impaired adaptive immunity [31] , additional studies will be required to establish whether impaired MAIT recovery after haploidentical and UCB transplants contributes to the higher incidence of infections seen after these types of transplants compared with those who received PBSCT [32] .
The mechanisms by which alterations in MAIT cell counts in blood could impact the risk of GVHD are unclear. Although previous studies showed that MAIT cells in blood were lower during acute exacerbation of autoimmune diseases [33] [34] [35] [36] [37] and 1 study suggested this may also be true after diagnosis of acute GVHD [38] , it was not determined in these studies whether the reduction in MAIT cell counts was a consequence of cytotoxic or immunosuppressive drugs used to treat inflammatory disease. We used a Cox regression model with MAIT cells as a time-dependent covariate to analyze the association of GVHD with MAIT cell counts collected at multiple times before the diagnosis of GVHD. The data indicate that low MAIT cell counts in blood precede the diagnosis of GVHD and are not a result of pharmacologic immunosuppression used to treat GVHD. Development of reproducible methods for detecting and quantitating MAIT cells in mucosal tissues will be pivotal in determining whether the increased risk of GVHD associated with low MAIT cell counts is because of their migration into inflamed sites before the presentation of clinically apparent GVHD or if MAIT cells possess regulatory activity that decreases the risk of GVHD. Examination of chemokine receptor expression on MAIT cells might provide additional insight into the mechanisms by which MAIT cell counts in blood fall before the onset of clinical acute GVHD. Our in vitro studies demonstrate that activated MAIT cells may have regulatory activity and suppress proliferation of CD4 + T cells, but additional studies will be required to determine the impact of MAIT cell suppression of GVHD in vivo. Human CD8αα T cells reside exclusively in the CD161 hi Vα7.2 + subset, and a CD8αα T cell subset in mice may have regulatory activity [39, 40] . Future investigation of the roles of CD8αα and CD8αβ CD161 hi cells will provide insight into their contributions to the pathogenesis of acute GVHD. Of note, there is emerging evidence that robust reconstitution of another bacterial ligand-responsive subset, invariant natural killer T cells, is associated with a reduced risk of GVHD and better overall survival [2, 3] .
This study provides new insights into MAIT cell reconstitution after HCT. These insights provide a foundation for future efforts to determine the effects of altering the content of MAIT cells in stem cell grafts or promoting MAIT cell recovery in the recipient by modifications of the microbiome or microbial ligands on clinical outcomes after allogeneic HCT.
